

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07C 69/013, 69/30, C07D 309/30, C07C 211/07, 211/14, 211/09, 211/10	A1	(11) International Publication Number: WO 00/17150 (43) International Publication Date: 30 March 2000 (30.03.00)
(21) International Application Number: PCT/IB99/01554 (22) International Filing Date: 17 September 1999 (17.09.99) (30) Priority Data: P-9800240 18 September 1998 (18.09.98) SI (71) Applicant (for all designated States except US): LEK PHARMACEUTICAL AND CHEMICAL COMPANY D.D. [SI/SI]; Verovskova 57, 1526 Ljubljana (SI). (72) Inventor; and (75) Inventor/Applicant (for US only): PFLAUM, Zlatko [SI/SI]; Češ, minova 25, 1230 Domzale (SI).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.
(54) Title: NEW SALTS OF HMG-CoA REDUCTASE INHIBITORS (57) Abstract <p>Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to <i>Aspergillus</i>, <i>Monascus</i>, <i>Nocardia</i>, <i>Ameycolatopsis</i>, <i>Mucor</i> or <i>Penicillium</i> genus, some are obtained by treating the fermentation products using the methods of chemical synthesis or they are the products of total chemical synthesis. The present invention relates to the new amine salts of HMG-CoA reductase inhibitors, the preparation thereof, the preparation of pure HMG-CoA reductase inhibitors via amine salts thereof, the use of the amine salts of HMG-CoA reductase inhibitors in the process for semisynthetic preparation of HMG-CoA reductase inhibitors, the use of the amine salts of HMG-CoA reductase inhibitors in the process for biotechnological modification of HMG-CoA reductase inhibitors as well as the conversion of the amine salts of HMG-CoA reductase inhibitors into the pharmaceutically acceptable salts of the HMG-CoA reductase inhibitors and the conversion of the amine salts of HMG-CoA reductase inhibitors into the HMG-CoA reductase inhibitors in the lactone form.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Title of the invention

New salts of HMG-CoA reductase inhibitors

5

Technical Field

Lovastatin, pravastatin, simvastatin, mevastatin, atorva-
statin and derivatives and analogs thereof are examples of
10 known as HMG-CoA reductase inhibitors which are used as
antihypercholesterolemic agents. The majority of them are
produced biotechnologically by fermentation using
microorganisms of different species identified as species
belonging to *Aspergillus*, *Monascus*, *Nocardia*,
15 *Amycolatopsis*, *Mucor* or *Penicillium* genus, some are
obtained by treating the fermentation products using the
methods of chemical synthesis, thus leading to semi-
synthetic substances, or they are the products of total
chemical synthesis.

20

The present invention relates to a new industrial process
for isolation and/or purification of HMG-CoA reductase
inhibitors via salts thereof with specific amines. The
invention enables to obtain the pure amine salts of HMG-
25 CoA reductase inhibitors from the fermentation broth in
case the substances are produced by biotechnological
(microbiological) processes, or from the reaction mixture
in case the substances are produced by semisynthetic or
total chemical synthesis. The step of forming salts with
30 amine may be one of the steps in the process for isolation
and/or purification of HMG-CoA reductase inhibitors or
precursor substances thereof. The amines described in the
present specification are very useful for the formation of
salts in the composition of media in processes for
35 biotechnological modification of HMG-CoA reductase

inhibitors or precursors thereof. The salts thus formed may be used as the starting substances or intermediates for the preparation of semisynthetic derivatives and analogs thereof, or by employing simple techniques known
5 from the literature, if required, to be converted into the pharmaceutically acceptable salts and lactones, respectively.

10 Prior Art

The processes for the isolation and purification of antihypercholesterolemic agents known from patent and technical literature include different combinations of
15 extraction, chromatography, lactonisation and crystallisation methods. Some of them additionally include the isolation and purification via different salts. In US Pat. Nos. 4,342,767 and 4,319,039, the ammonium salt of lovastatin (in the carboxylate form) is isolated directly from
20 the organic phase which has been extracted from the fermentation medium. In the same patent the preparation of ethylenediamine, tetramethylammonium, potassium and N-methylglucamine salts as well as the salts of different amino acids such as L-lysine, L-arginine and L-ornithine
25 is also described. The aforementioned salts are prepared from the already purified substance and the option for their use in the process of isolation or purification is not mentioned. GB 2055100 A also describes the formation of the sodium and calcium salts of lovastatin, which
30 comprises the extraction in methanol, two steps of preparative liquid reverse-phase chromatography, crystallisation from methanol and recrystallisation from ethanol, and the conversion into the salt using an aqueous solution of sodium or calcium hydroxide. However, without
35 including various chromatography methods, the methods de-

scribed do not yield a product of the purity comparable to the product obtained by using the present invention. US Pat. No. 4,346,227 discloses a process for the preparation of the sodium salt of pravastatin wherein chromatographic techniques are also used but the final product is obtained only after lyophilisation which is not an economical process in a large scale production operations. EP 65,835 discloses the preparation of the L-ornithine and t-octylamine salts of tetrahydro-M-4 or tetrahydro-IsoM-4 (wherein M4 denotes a specific HMG-CoA reductase inhibitor, M-4 and IsoM-4 representing the isomers hydroxylated at 6- and 3-biphenyl ring position, respectively, and "tetrahydro" means that the condensed biphenyl ring system is fully hydrogenated) as final products, that is from the respectively purified sodium salts thereof, but not as intermediates via which the isolation would be carried out. Other salts of tetrahydro- M-4 or IsoM-4 with ammonia, an amino acid or an organic amine are also contemplated as final products, including octylamine, 2-ethylhexylamine, benzylamine, α -methyl-benzylamine, phenethylamine, dibenzylamine, N-methylbenzylamine, N,N-dimethylbenzylamine, N,N-diethylbenzylamine, N-ethyl-N-methylbenzylamine, tribenzylamine, cyclopentylamine, cyclohexylamine cycloheptylamine, N-methylcyclopentylamine, N-ethylcyclohexylamine, N-ethylcycloheptylamine, dicyclohexylamine, N,N-dimethylcyclopentylamine, N,N-dimethylcyclohexylamine, N,N-diethylcycloheptylamine, pyrrolidine, N-methylpyrrolidine, piperidine, N-methylpiperidine and morpholine. GB 2073199 A also discloses the preparation of different salts of HMG-CoA reductase inhibitors from the already isolated substance in the lactone form. US Pat. Nos. 5,763,653 and 5,763,646 disclose the preparation of the cyclopropylamine and n-butylamine amides of lovastatin and their use in a process

of chemical semisynthesis of simvastatin. US Pat. No. 5,403,860 discloses, as final products, amine salts of octahydronaphthalene oxime derivatives of HMG-CoA inhibitors, the derivatives deriving from ML-236A, ML-236B, MB-530A and MB-530B. As final amine salts, t-octylamine, dibenzylamine, dicyclohexylamine, morpholine, D-phenylglycine alkylester and D-glucosamine salts are mentioned.

10

Technical Problem

In industry there exists a constant need for rationalisation of the production and shortening of the production processes as well as for the use of least expensive starting raw materials or intermediate substances. To date the isolation of the final products in the case of HMG-CoA reductase inhibitors has been a multi-stage process wherein each step adds its share to the losses resulting in the final yield rarely greater than 60%. In addition, a product in the lactone form or lactone converted into the sodium salt is used as the starting substance in the process of semisynthesis (e.g. in a process for preparing simvastatin) or biochemical conversion (e.g. in a process for preparing pravastatin). The preparation of lactone is one of the least economical steps in the production of HMG-C-A reductase inhibitors since losses in the course of the conversion from the acid into the lactone form and optionally further into the salts are greater than 20%. Therefore, there is a constant need for the starting substances and/or the intermediate substances which would be sufficiently pure, with small losses during their conversion, low costs, and the preparation per se should be technologically simple.

35


Description of the invention

In our developmental and research work we have surprisingly found that HMG-CoA reductase inhibitors form the salts with certain amines which crystallise from mother liquor once they are formed. It has surprisingly been found that crystals of the amine salt of the desired HMG-CoA reductase inhibitor of high purity may be obtained from the liquors containing a large number of impurities and undesired HMG-CoA reductase inhibitor analogs. Contrary to the statements from US Pat. No. 5,403,860 that lower yields are obtained when using the salts of HMG-CoA reductase inhibitor as starting or intermediate substances in a process for preparing the substances (Ia) mentioned below, we have surprisingly found that, when using the amine salts of HMG-CoA reductase inhibitors according to the present invention, the yields and the purity of the prepared HMG-CoA reductase inhibitors are equal to or greater than when using the HMG-CoA reductase inhibitors in the lactone form.

Exemplified Formula Ia

25 R_1 : CH_3 , CH_2OH , OH

a and b: both may be double bonds, one of them may be a single bond, both may be single bonds




Furthermore, we surprisingly discovered that in processes for the biotechnological modification of HMG-CoA reductase inhibitors the formation of amine salts of HMG-CoA reductase inhibitors in the medium which derives from the fermentation liquor provides, in comparison with the mere metal salts as described in publicly accessible literature, an efficient means for the isolation and/or purification of HMG-CoA reductase inhibitors by means of simple crystallisation. The amines which are described in the present specification and which readily form salts with HMG-CoA reductase inhibitors are thus particularly suitable as auxiliary materials or processing aids for the isolation and/or purification of HMG-CoA reductase inhibitors. Furthermore, they can be excellently used as starting materials or intermediates of semisynthetic preparation or biotechnological modification of HMG-CoA reductase inhibitors and, furthermore, for the conversion into pharmaceutically acceptable salts or into the lactone form of the respective HMG-CoA reductase inhibitors. Accordingly, the novel amine salts of HMG-CoA reductase inhibitors of the present invention are also highly valuable as such.

The present invention provides:

- 25 a) the novel salts of HMG-CoA reductase inhibitors with organic amines as specified in claim 1, wherein those specific salts are excluded which are disclosed in the prior art, but in different contexts as mentioned above,
- b) a process for the preparation of salts of HMG-CoA reductase inhibitors with amines as specified in claim 5,
- 30 c) a use of salts of HMG-CoA reductase inhibitors with amines as processing aids or starting substances or intermediate substances in various processes as specified in claim 18,

- d) a process for the preparation of the pure HMG-CoA reductase inhibitors from/via amine salts thereof, as specified in claim 27,
- e) a process for the semisynthetic preparation of HMG-CoA reductase inhibitors, wherein the amine salts of HMG-CoA reductase inhibitors are used as the starting substances, as specified in claim 30,
- f) a process for the biotechnological modification of HMG-CoA reductase inhibitors, wherein one of the components of the medium is the amine salt of HMG-CoA reductase inhibitors, as specified in claim 33,
- g) a process for the conversion of the amine salts of HMG-CoA reductase inhibitors into the pharmaceutically acceptable salts of HMG-CoA reductase inhibitors, as specified in claim 37, and
- h) a process for the conversion of the amine salts of HMG-CoA reductase inhibitors into HMG-CoA reductase inhibitors in the lactone form, as specified in claim 41.
- 20 The amine which is used according to the present invention for the formation of the salts with a HMG-CoA reductase inhibitor is selected from the group consisting of organic amines of the following formulae I and II:

25 a)



30 wherein:

- a) R_1 , R_2 , R_3 and R_4 independently denote:
- a hydrogen atom
 - a straight or a branched alkyl group having 1 to 8 carbon atoms, or


- a cycloalkyl group having 3 to 8 carbon atoms, or
- an arylalkyl group wherein the alkyl group is methyl or ethyl and the aryl group is phenyl, which is optionally substituted by an N-alkyl or N,N-dialkyl group wherein
- 5 the alkyl group is alkyl having 1 to 4 carbon atoms, or
- an arylalkyl group which is optionally substituted by one or more substituents,
- a hydroxyalkyl group having 2 to 4 carbon atoms, or
- an aminoalkyl group having 2 to 4 carbon atoms, which
- 10 are optionally substituted by an N-alkyl or N,N-dialkyl group wherein the alkyl group is alkyl having 1 to 4 carbon atoms;

X denotes a hydrogen atom, a hydroxyl group, a halogen or a methyl group;

- 15 m and n independently denote an integer from 0 to 5; or
- a2) NR_1R_2 or NR_3R_4 denote a heterocyclic ring having 3 to 7 methylene groups, one of these groups being optionally substituted by an oxygen or a sulphur atom or an imine group; X, m and n are as defined above;

20

b)



II

25

wherein:


- b1) R'_1 , R'_2 , and R'_3 are the same or different and denote hydrogen, alkyl, alkenyl, amino- or hydroxy- or alkoxy-substituted alkyl or alkenyl, or substituted amino-
- 30 substituted alkyl or alkenyl, provided that R'_1 , R'_2 , and R'_3 are not hydrogen at the same time; or

- b2) R'_1 and R'_2 , and optionally R'_3 , together with the nitrogen atom form an optionally substituted heterocyclic ring system including the nitrogen atom as a ring member, and optionally including an additional hetero atom, and if
- 5 R'_3 is not part of the ring system it is independently selected from hydrogen, alkyl, alkenyl, amino- or hydroxy- or alkoxy-substituted alkyl, or substituted amino-substituted alkyl; or
- b3) R'_1 is an optionally substituted cyclic group of
- 10 general formula III,



- wherein m is zero or an integer from 1 to 5, R' is
- 15 optionally substituted aliphatic hydrocarbon cyclic system having 3 to 8 carbon atoms in the ring, R'_4 is hydrogen, or alkyl, amino- or hydroxy- or alkoxy- substituted alkyl, or substituted amino- substituted alkyl, or a group of the same general formula as R'_1 as defined herein above; R'_2
- 20 and R'_3 are the same as R'_1 or hydrogen, alkyl, alkenyl, amino- or hydroxy- or alkoxy- substituted alkyl, or substituted amino- substituted alkyl or alkenyl; or
- b4) R'_1 is an optionally substituted aryl group of general formula IV:

25



30

wherein R'_5 is hydrogen or one or more substituents, and m is zero or an integer from 1 to 5; and R'_2 and R'_3 may be independently hydrogen, alkyl, amino- or hydroxy- or

alkoxy- substituted alkyl, or substituted amino-substituted alkyl, or groups of the same general formula R'_1 .

- Substitutions which are not explicitly specified are usual
- 5 "inert" substituents, such as halogens, a hydroxyl group, alkyl having 1 to 4 carbon atoms, alkoxyl having 1 to 4 carbon atoms, acyloxyl having 1 to 4 carbon atoms and esterified carboxyl having 1 to 4 carbon atoms.
- 10 Advantageous examples of amines which form the salts with HMG-CoA reductase inhibitors are: (\pm)-1,2-dimethylpropylamine, 3-(2-aminoethylamino)-propylamine, n-butylamine, secondary butylamine, tertiary butylamine (TBA), dibutylamine, tertiary amylamine, cyclopentylamine, cyclohexylamine, cycloheptylamine, dicyclohexylamine (DCHA), N-methylcyclohexylamine , N,N'-diisopropylethylenediamine (DIPEDA), N,N'-diethylenediamine, N-methyl-1,3-propanediamine, N-methylethylenediamine, N,N,N',N'-tetramethyl-1,2-diaminoethane, N,N,N',N'-tetramethyl-1,4-diaminobutane, N,N,N',N'-tetramethyl-1,6-diaminohexane, 1,2-dipiperidinethane, dipiperidinemethane, 2-amino-3,3-dimethylbutane, N,N-dimethylcyclohexylamine, neopentylamine, adamantylamine, N,N-diethylcyclohexylamine, N-isopropylcyclohexylamine, N-methylcyclohexylamine, cyclobutylamine and norborylamine. Preferably in terms of crystallisation efficiency, combined with low toxicity and low costs, the amine is selected from the group consisting of n-butylamine, secondary butylamine, TBA, dibutylamine, tertiary amylamine, cyclohexylamine, DCHA, N-methylcyclohexylamine and DIPEDA. The amine may particularly be selected from the group consisting of TBA, DIPEDA, DCHA and N-methylcyclohexylamine.
- 25
- 30

The amines specified above are advantageous over the direct isolation via the salts with ammonia in terms of purification efficiency. Furthermore, amines having a larger organic group, and especially those having bulky groups, generally show a more readily crystallisation and to a lower extent form salts with unwanted side products when compared with amines having small organic groups. Accordingly, amines having at least one hydrocarbon residue with secondary or tertiary carbon atoms, or with cyclic hydrocarbon structure (either aromatic or aliphatic), and organic diamines are particularly suitable for the present invention.

Any type of HMG-CoA reductase inhibitors can be used according to the present invention. Those HMG-CoA reductase inhibitors selected from the group consisting of mevastatin, pravastatin, lovastatin, simvastatin, fluvastatin and atorvastatin have shown good results and are particularly preferred.

For isolating and purifying the desired HMG-CoA reductase inhibitor, the amine salt is most effectively formed directly from the crude medium of the respective HMG-CoA reductase inhibitor, which crude medium is usually derived from a fermentation broth as the result of a biotechnological process or from a reaction mixture as the result of a semisynthesis or the total synthesis and usually contains the desired HMG-CoA reductase inhibitor together with unwanted side products and impurities. The crude medium may preferably contain the HMG-CoA reductase inhibitor in its acid form, and the formation of the amine salt may be effected by simply adding the amine to the crude medium. The crude medium may be an organic phase or a mixture of an organic or an aqueous phase where the

impure HMG-CoA reductase inhibitor is present in an organic solvent, such as ethyl acetate, ether or acetonitrile. Ethyl acetate is preferred as the organic solvent. After the biotechnological treatment, the crude
5 medium in the organic phase is preferably obtained from the fermentation broth by a process including the step of extracting the HMG-CoA reductase inhibitor into the aforementioned organic solvent.

The process for the preparation of the amine salts of HMG-CoA reductase inhibitors may include the following steps:
10

- a) contacting the medium containing the HMG-CoA reductase inhibitor, which is preferably in the acid form in an organic solvent, with at least one of the amines specified above,
- 15 b) optionally: forming crystallisation nuclei by known techniques,
- c) filtering the crystals crystallised out
- d) washing the crystals with an organic solvent, and
- e) drying the crystals

20

The term "contacting" includes the known techniques for the preparation of the salts from substances with acid properties and substances with alkaline properties. The crystallisation is preferably carried out at a temperature
25 between 0 and 30°C, more preferably between 4 and 22°C.

The term "organic solvent" means organic solvents which are used in industry such as ethyl acetate, butyl acetate, ether and acetonitrile, including their aqueous mixtures.

30 Since the amines specified above effectively form salts with the HMG-CoA reductase inhibitors, they are also particularly suitable as auxiliary materials or processing

aids in a process for preparing the HMG-CoA reductase inhibitor in a purified form. Previously isolated HMG-CoA reductase inhibitors can be thus obtained in a higher purity. The purified form is usually prepared by
5 crystallisation. Accordingly, the present invention provides a process for the isolation and/or purification of a HMG-CoA reductase inhibitor.

In further aspects of the present invention, the salt as
10 specified above is suitably used as the starting substance or the intermediate substance in a process for preparing the HMG-CoA reductase inhibitor which is in a modified form, in a pharmaceutically active salt form or in the lactone form. Specifically, the modified form is obtained
15 by chemical modification or biotechnological modification, which modifications are known to those skilled in the art. The pharmaceutically active salt is preferably a metal salt, such as the sodium salt or the calcium salt.

In this connection, the term "a process for the semi-
20 synthetic preparation of HMG-CoA reductase inhibitors" means the preparation of HMG-CoA reductase inhibitors using any of the known chemical modifications of the HMG-CoA reductase inhibitors. An example of such process is the semisynthesis of simvastatin from lovastatin as the
25 starting substance. Most preferably, the TBA salt of lovastatin is used as the starting substance.

Furthermore, the term "a process for the biotechnological modification of HMG-CoA reductase inhibitors" means the preparation of HMG-CoA reductase inhibitors using
30 microorganisms or enzymatic systems thereof for modifying HMG-CoA reductase inhibitors. An example of such process is the biotechnological conversion of mevastatin into pravastatin. The amine salt is preferably the TBA salt.

- Furthermore, the term "a process for the conversion of the amine salts of HMG-CoA reductase inhibitors into the pharmaceutically acceptable salts of HMG-CoA reductase inhibitors" includes processes for the preparation of HMG-CoA reductase inhibitors by one of the known methods wherein the amine salts of HMG-CoA reductase inhibitors are used as the starting substance. Specific examples of converted salts are the sodium salts of pravastatin and fluvastatin and the calcium salt of atorvastatin.
- Furthermore, the term "conversion of the amine salts of HMG-CoA reductase inhibitors into HMG-CoA reductase inhibitors in the lactone form" includes processes for the preparation of HMG-CoA reductase inhibitors in the lactone form by one of the known methods wherein the amine salts of HMG-CoA reductase inhibitors are used as the starting substance. Examples of HMG-CoA reductase inhibitors converted into the lactone form are lovastatin, mevastatin or simvastatin.

20

The present invention is illustrated but in no way limited by the following examples.

25

EXAMPLES

Example 1

- Preparation of free acid of mevastatin and conversion thereof into salt thereof with tertiary butylamine (TBA)

Mevastatin (200 g) was suspended in 30% volume/volume (v/v) aqueous acetonitrile solution (2500 ml), 3 equivalents of triethylamine were added and the mixture was heated to 80°C and stirred for 30 minutes. After the

completed reaction, acetonitrile was evaporated, the remaining solution was acidified to pH 4 with phosphoric acid and extracted into ethyl acetate (2 x 1000 ml). The pooled extracts were dried by the addition of 30 g of sodium sulphate, the desiccant was filtered off and the solution was concentrated (950 ml). TBA (1.5 equivalents) was added to the solution and crystallisation was carried out for 30 minutes at 8°C. The crystals formed were filtered and washed with ethyl acetate (2 x 100 ml) and subsequently dried at 40°C for 15 hours. The crystals obtained (the TBA salts of mevastatin 215 g) were white in colour with a HPLC purity of 96.8%. The yield of the hydrolysis and crystallisation was 91%.

15 Example 2

Preparation of the sodium salt of mevastatin from the TBA salt of mevastatin

The TBA salt of mevastatin (1 g), obtained by the process disclosed in example 1, was dissolved in 3 ml of ethanol (96% v/v) and sodium hydroxide (40 g/L of ethanol) was added. The resulting mixture was precipitated in the ethyl acetate (60 ml). After the crystallisation (30 min) at 8°C the crystals were filtered off, washed with ethyl acetate and dried. The product: crystals of the sodium salt of mevastatin (0.65 g) pale brown in colour with a HPLC purity of 98%.

Example 3

Isolation of the TBA salts of lovastatin from the fermentation broth

A fermentation broth (160 L) obtained by the fermentation with a microorganism *Aspergillus terreus* ATCC 20544 and having a lovastatin content of 1 g/L was transferred from the fermenter into the tank (400 L) and pH was adjusted to 10 with the addition of 1M aqueous sodium hydroxide

solution. After 10 minutes of vigorous stirring the pH of the broth was decreased to 9 by adding 1M sulphuric acid solution and the biomass was filtered off. The filtrate obtained was acidified to a pH value of 6.5 with 1M
5 sulphuric acid solution and 160 L of ethyl acetate was added. The slurry was subsequently stirred for 20 minutes. The aqueous and ethyl acetate phases were separated by extraction centrifuge and the ethyl acetate extract was concentrated in a rotavapor to the volume of 14 L. The
10 concentration of lovastatin in the form of free acid in concentrated ethyl acetate extract was 10.1 g/L. To the obtained lovastatin solution (HPLC purity 72.7%) in the form of free acid in ethyl acetate (800 ml) 1.05 equivalents of TBA were added. After crystals were
15 crystallised out, they were filtered off, washed with ethyl acetate (2 x 50 ml) and dried in a vacuum oven at 35°C for 24 hours. The yield: 8.06 g of crystals of the TBA salt of lovastatin with a HPLC purity of 99.2%.

20

Example 4

Preparation of the salt of lovastatin with tertiary amylamine

Lovastatin (5 g) was treated according to the process for
25 hydrolysis disclosed in example 1 and sodium salt thereof (4.8 g) was prepared and dissolved in 100 ml of water. pH was adjusted to 4 with phosphoric acid (10% aqueous solution) and the formed free acid of lovastatin was extracted from the water phase into ethyl acetate (2 x 100
30 ml). The pooled ethyl acetate extracts were dried with sodium sulphate, the solution was filtered off and concentrated to ca. 100 ml. To the solution, prepared in the above manner (ca. 100 ml), 1.05 equivalents of tertiary amylamine were added. After crystals were
35 crystallised out, they were filtered off, washed with ethyl acetate (2 x 10 ml) and dried in a vacuum oven (35°C,

24 hours). The yield: 4.8 g of crystals of the tertiary amylamine salt with a HPLC purity of 98.6%.

5 Example 5

Preparation of pravastatin in the free acid form and conversion into the (\pm)-1,2-Dimethylpropylamine salt thereof

Pravastatin (11 g, HPLC purity 97.2%) in the form of Na salt was dissolved in water (100 ml) and pH was adjusted to 4 with phosphoric acid (10% aqueous solution). The resulting free acid was extracted from the water phase into ethyl acetate (2 x 100 ml). The pooled ethyl acetate extracts were dried with sodium sulphate, the solution was filtered off and concentrated to a volume of ca. 100 ml.

To the concentrate (9 ml) thus obtained, 1.5 equivalents of (\pm)-1,2-dimethylpropylamine were added. After crystals were crystallised out, they were filtered off, washed with ethyl acetate (2 x 10 ml) and dried in a vacuum oven at 35°C. The yield: crystals yellow in colour with a HPLC purity of 98.28%.

Examples 6-13

The conversion of the free acid form of pravastatin into the amine salt form as described in example 5 was repeated with other amines.

The amines used and results are shown in the Table below:

Ex.	AMINE	EFFECT	HPLC purity
6	3-(2-aminoethylamino)-propylamine	an oil is formed*	-
7	N,N'-diisopropyl-ethylenediamine	pale yellow crystals	99.3%
8	N,N'-diethyl-ethylenediamine	yellow crystals	99.3%
9	N-methyl-1,3-propanediamine	an oil is formed*	-
10	N-methylethylenediamine	an oil is formed*	-
11	secondary-butylamine	white crystals	98.9%
12	tertiary-butylamine (TBA)	yellowish crystals	97.4%
13	tertiary-amylamine	off-white crystals	97.9%

* from an oil formed, crystals are crystallised out overnight at 4°C .

5 Example 14

Preparation of the salt of pravastatin with secondary butylamine from the crude sodium salt of pravastatin

- According to the process described in example 5, pravastatin in the free acid form was prepared from the sodium salt of pravastatin (HPLC purity 83.6%). Further
- 10 the salt of pravastatin with secondary butylamine was prepared by the process described in example 5. White crystals with a HPLC purity of 97.3% were obtained.

15 Example 15

Preparation of the sodium salt of pravastatin from the TBA salt of pravastatin (1)

8.9 g of the TBA salt of pravastatin as obtained in example 12 were dissolved in 22 ml of ethanol (96%) and

subsequently precipitated in 450 ml of ethyl acetate. Crystallisation was carried out at 8°C for 60 minutes, the crystals formed were filtered off, washed with two 50 ml portions of ethyl acetate and dried at 40°C for 5 hours. 1 g of the recrystallised TBA salt of pravastatin, obtained in the above-described manner, was dissolved in 5 ml of ethanolic solution of 0.43N NaOH and precipitated in 60 ml of ethanol. After 30 minutes at 8°C, crystals formed were filtered off and dried. The formed crystals of the sodium salt of pravastatin (0.75 g) were dark yellow in colour.

Example 16

Preparation of the sodium salt of pravastatin from the TBA salt of pravastatin (2)

The process described in example 15 was repeated wherein 1 g of the recrystallised TBA salt of pravastatin was dissolved in 3 ml of water, instead of ethanolic solution of 0.43N NaOH, and subsequently an aqueous sodium carbonate solution (equivalent) was added. The obtained solution was diluted with 5 ml of ethanol and the resulting sodium salt was precipitated with ethyl acetate. After 30 minutes at 8°C, crystals formed were filtered off and dried. The formed crystals of the sodium salt of pravastatin (0.65 g) were yellow in colour.

Example 17

Preparation of pravastatin from the TBA salt of mevastatin

PREPARATION OF INOCULUM FOR PRODUCTION

The colonies of microorganism *Amycolatopsis orientalis* ATCC 19795 were transferred to a sterile potter and homogenised. The resulting colonies were transferred to agar slopes and incubated in the thermostat at 26° to 30°C for 7 to 14 days. During that time surfaces of agar slopes were overgrown by cultures of homogeneous, folded, smooth,

- white to pale greyish-blue mycelium. Further, 10 ml of sterile water was poured onto the agar slopes, the culture was scraped off with the pipette and the contents transferred into the potter. A portion (0.5 to 1 ml) of the resulting culture was then inoculated into the vegetative medium.

Agar medium for the preparation of agar slopes and petri plates:

10

Raw material	Amount
Dextrin	10 g
Consumer's glucose	5 g
Casaminic acid	3 g
Yeast extract	4 g
CaCO ₃	1 g
Agar	15 g
Sterile water	up to 1000 ml

No pH adjustment needed.

VEGETATIVE PHASE OF FERMENTATION

- The inoculum grown on the slope at 26° to 30°C for 10 days and prepared according to the above-described method was inoculated in a 500-ml Erlenmeyer flask containing 50 ml of the vegetative medium. After 24 hours of shaking at 220 rpm at 28°C, the culture was transferred onto the fermentation medium.

- 20 Vegetative medium:

Raw material	Amount
Corn starch for fermentation	20 g
Soybean flour for fermentation	14 g

Glucose	10 g
Yeast extract	5 g
NaH ₂ PO ₄ x 2H ₂ O	3.3 g

Tap water to 1000 ml

5 *CONVERSION OF THE TBA SALTS OF MEVASTATIN INTO PRAVASTATIN*

- The contents of fifteen Erlenmeyer flasks with the culture, prepared according to the above-described method, were used to inoculate the fermenter (50 L) with 30 L of fermentation medium. After 20-hour fermentation, the
- 10 solution of the TBA salt of mevastatin and glucose (1200 g of glucose and 70 g of TBA salt of mevastatin (assay of mevastatin: 80%) dissolved in 5 L of water) was continually added to the medium at the flow rate 2 ml/min. During the fermentation 70% oxygen saturation of the
- 15 medium was maintained by stirring with the frequency between 300 and 600 rpm. Analyses of the concentration of pravastatin in the fermentation broth showed the total final concentration of pravastatin in the fermentation broth to be 690 g/kg of broth after 76 hours of
- 20 fermentation at temperature between 24° and 30°C, indicating a 40% conversion of mevastatin into pravastatin.

Fermentation medium:

Raw material	Amount
Corn starch for fermentation	20 g
Soybean flour for fermentation	5 g
Glucose	10 g
Yeast extract	5 g
Antifoam agent	10 g

All raw materials were dissolved in tap water, the pH was then adjusted to 7.4.

5

Example 18

10 *Preparation of TBA salt of simvastatin*

Simvastatin (1.95 g) was suspended in 50 ml of 30% (v/v) acetonitrile, triethylamine (1 ml) was added and the solution was heated for 20 minutes at 70°C. After completion of reaction acetonitrile was evaporated from
15 the solution, the remaining solution was acidified to pH 4 with phosphoric acid. Simvastatin in the acid form was extracted into ethyl acetate (2 x 50 ml) and the pooled extracts were dried with 2 g of sodium sulphate. The desiccant was filtered off and the ethyl acetate solution
20 was concentrated to 20 ml. To the solution 1.05 equivalents of TBA were added and crystallisation was carried out for 1 hour at 8°C. The product was filtered off and dried at 40°C for 1 hour. The yield: 2 g of the TBA salt of simvastatin.

25

Example 19

Conversion of the TBA salt of simvastatin into simvastatin lactone

The TBA salt of simvastatin (1.6 g), obtained by the
30 process disclosed in example 18, was dissolved in water (36 ml), the solution was then acidified to pH 3.7 with an aqueous phosphoric acid solution and simvastatin in the acid form was extracted into ethyl acetate (2 x 50 ml). The pooled extracts were dried with sodium sulphate (2 g)
35 and the desiccant was then filtered off. The ethyl acetate

solution was concentrated to 20 ml. To the solution trifluoroacetic acid (0.5 ml) was added and the reaction mixture was heated for 25 minutes at 50°C. After completion of the reaction, the ethyl acetate solution was extracted
5 with 5% (w/w) aqueous solution of ammonium hydrogen carbonate. The organic phase was dried with sodium sulphate (2 g), the desiccant was filtered off and the ethyl acetate solution was concentrated to 4 ml. Crystallisation was carried out for 1 hour at 8°C. The
10 product was then filtered off and dried at 40°C for 1 hour. The yield: 0.9 g of simvastatin in the acid form.

Example 20

Preparation of free acid of simvastatin

15 Simvastatin (20 g) was dissolved in the mixture of water (80 ml) and 8M KOH (18 ml). The solution was stirred in nitrogen atmosphere for two hours at room temperature. After that 120 ml of ethyl acetate was added and pH was adjusted to 2-3 with 5% aqueous solution of HCl. Ethyl
20 acetate phase was washed with mixture of water (100 ml), 5% aqueous solution of HCl and 5% aqueous solution of NaCl (50 ml). The obtained ethyl acetate phase was then dried for three hours with addition of 20 g MgSO₄ anhydrite and filtrated.

Preparation of amine salt

After that 18 ml of N-methylcyclohexylamine was added into the ethyl acetate phase. After two days at temperature between 0 and 5°C crystals of simvastatin N-methylcyclohexylamine salt were formed. Obtained crystals were
30 filtered off and washed with 20 ml of ethyl acetate, 40 ml ethyl acetate/n-heptane (1:1) and 40 ml of pentane. The yield: 20.5 g of N-methylcyclohexylamine salt of

simvastatin. The yield calculated to the starting simvastatin was 79%.

The same results were obtained also with cyclohexylamine
5 (by the use of the same method).

Example 21

10 **Preparation of pravastatin in purified form**

Pravastatin (30 g, HPLC purity 90.2%) in the form of Na salt was dissolved in water (100 ml) and pH was adjusted to 3 with HCl (10% aqueous solution). The resulting free acid was extracted from the water phase into ethyl acetate
15 (3 x 200 ml). The pooled ethyl acetate extracts were dried with sodium sulphate, the solution was filtered off and 7.604 g of N-methylcyclohexylamine was added (drop by drop at intensive stirring). After crystals were crystallised out, they were filtered off and re-crystallised from the
20 mixture of ethyl acetate/methanol. The yield: 21 g of crystals of pravastatin N-methylcyclohexylamine salt with a HPLC purity of 99.28%.

Example 22

25 **Preparation of free acid of atorvastatin**

Calcium salt of atorvastatin (3 g) was suspended in 100 ml water. The pH was adjusted with phosphoric acid to 4 and after that free acid of atorvastatin was extracted with ethyl acetate (3 x 100 ml). Combined ethyl acetate extract
30 was dried and 2.7 g of oil containing atorvastatin in the free acid form was obtained.

Preparation of amine salt

1 g of atorvastatin in the free acid form was dissolved in acetonitrile (100 ml) and 1.1 molar equivalents of TBA was


added. The obtained mixture was concentrated to 30 ml and after four hours at 8 °C the tBA salt of atorvastatin crystallised. White precipitate was filtered off and dried in a rotary evaporator. Yield: 1 g of TBA salt of
5 atorvastatin.

Example 23

1 g of atorvastatin in the free acid form was dissolved in
10 methanol (20 ml) and 1.1 molar equivalents of dicyclohexylamine (DCHA) in 50 ml of n-hexane was added. After four hours at 8 °C the DCHA salt of atorvastatin crystallised. White precipitate was filtered off and dried in a rotary evaporator. Yield: 1.1 g of DCHA salt of
15 atorvastatin.

Claims

1. The salt of a HMG-CoA reductase inhibitor with
 5 an amine, characterised in that said amine is selected from the group consisting of amines of the following formulae I and II:



wherein:

- al) R_1 , R_2 , R_3 and R_4 independently denote:
- 15
- a hydrogen atom;
 - a straight or a branched alkyl group having 1 to 8 carbon atoms;
 - a cycloalkyl group having 3 to 8 carbon atoms;
 - an arylalkyl group wherein the alkyl group is methyl or

20 ethyl and the aryl group is phenyl, which is optionally substituted by an N-alkyl or N,N-dialkyl group wherein the alkyl group is alkyl having 1 to 4 carbon atoms;

 - an arylalkyl group which is optionally substituted by one or more substituents;

25

 - a hydroxyalkyl group having 2 to 4 carbon atoms; or
 - an aminoalkyl group having 2 to 4 carbon atoms, which are optionally substituted by an N-alkyl or N,N-dialkyl group wherein the alkyl group is alkyl having 1 to 4 carbon atoms;

30

 - X denotes a hydrogen atom, a hydroxyl group, a halogen or a methyl group;
 - m and n independently denote an integer from 0 to 5; or

- a2) NR_1R_2 or NR_3R_4 denote a heterocyclic ring having 3 to 7 methylene groups attached to a hydrogen atom, one of these groups being optionally substituted by an oxygen or a sulphur atom or an imine group; and X , m and n are the same as defined above;

b)



10

wherein:


- b1) R'_1 , R'_2 , and R'_3 are the same or different and denote hydrogen, alkyl, alkenyl, amino- or hydroxy- or alkoxy- substituted alkyl or alkenyl, or substituted amino- substituted alkyl or alkenyl, provided that R'_1 , R'_2 and R'_3 are not hydrogen at the same time; or
- b2) R'_1 and R'_2 , and optionally R'_3 , together with the nitrogen atom form an optionally substituted heterocyclic ring system including the nitrogen atom as a ring member, and optionally including an additional hetero atom, and if R'_3 is not part of the ring system it is independently selected from hydrogen, alkyl, alkenyl, amino- or hydroxy- or alkoxy- substituted alkyl, or substituted amino- substituted alkyl; or
- b3) R'_1 is an optionally substituted cyclic group of general formula III,



- wherein m is zero or an integer from 1 to 5, R' is optionally substituted aliphatic hydrocarbon cyclic system having 3 to 8 carbon atoms in the ring, R'_4 is hydrogen,

- alkyl, amino- or hydroxy- or alkoxy- substituted alkyl, substituted amino- substituted alkyl, or a group of the same general formula as R'_1 as defined herein above; R'_2 and R'_3 are the same as R'_1 or hydrogen, alkyl, alkenyl, amino- or hydroxy- or alkoxy- substituted alkyl, or substituted amino- substituted alkyl or alkenyl; or
- b4) R'_1 is an optionally substituted aryl group of general formula IV:

10



- wherein R'_5 is hydrogen or one or more substituents, and m is zero or an integer from 1 to 5; and R'_2 and R'_3 may be independently hydrogen, alkyl, amino- or hydroxy- or alkoxy- substituted alkyl, or substituted amino- substituted alkyl, or groups of the same general formula R'_1 ;

20

provided that

when the HMG-CoA reductase inhibitor is lovastatin, the amine is not tetramethylamine or ethylenediamine;

- when the HMG-CoA reductase inhibitor is tetrahydro-M-4 or tetrahydro-IsoM-4, the amine is not octylamine, 2-ethylhexylamine, benzylamine, α -methyl-benzylamine, phenethylamine, dibenzylamine, N-methylbenzylamine, N,N-dimethylbenzylamine, N,N-diethylbenzylamine, N-ethyl-N-methylbenzylamine, tribenzylamine, cyclopentylamine, cyclohexylamine, cycloheptylamine, N-methylcyclopentylamine, N-ethylcyclohexylamine, N-ethylcycloheptylamine, dicyclohexylamine, N,N-dimethylcyclopentylamine, N,N-dimethylcyclohexylamine, N,N-diethylcycloheptylamine,

30

pyrrolidine, N-methylpyrrolidine, piperidine, N-methylpiperidine or morpholine; and

when the HMG-CoA reductase inhibitor is the octahydronaphthalene oxime derivative of ML-236A, ML-236B, MB-530A or MB-530B, the amine is not t-octylamine, dibenzylamine, dicyclohexylamine or morpholine.

2. The salt of a HMG-CoA reductase inhibitor with an amine according to claim 1, wherein the amine is selected from the group consisting of (\pm)-1,2-dimethylpropylamine, 3-(2-aminoethylamino)-propylamine, n-butylamine, secondary butylamine, tertiary butylamine, dibutylamine, tertiary amylamine, cyclopentylamine, cyclohexylamine, cycloheptylamine, dicyclohexylamine, N-methylcyclohexylamine, N,N'-diisopropylethylenediamine, N,N'-diethylenediamine, N-methyl-1,3-propanediamine, N-methylethylenediamine, N,N,N',N'-tetramethyl-1,2-diaminoethane, N,N,N',N'-tetramethyl-1,4-diaminobutane, N,N,N',N'-tetramethyl-1,6-diaminohexane, 1,2-dipiperidinethane, dipiperidinemethane, 2-amino-3,3-dimethylbutane, N,N-dimethylcyclohexylamine, neopentylamine, adamantylamine, N,N-diethylcyclohexylamine, N-isopropylcyclohexylamine, N-methylcyclohexylamine, cyclobutylamine and norborylamine.

25


3. The salt of a HMG-CoA reductase inhibitor with an amine according to claim 1, wherein the amine is selected from the group consisting of n-butylamine, secondary butylamine, tertiary butylamine, dibutylamine, tertiary amylamine, cyclohexylamine, dicyclohexylamine, N-methylcyclohexylamine and N,N'-diisopropylethylenediamine.

30

4. The salts of a HMG-CoA reductase inhibitor with an amine according to any one of claims 1 to 3, wherein the HMG-CoA reductase inhibitor is selected from the group consisting of mevastatin, pravastatin, lovastatin, simvastatin, fluvastatin and atorvastatin.

5. A process for preparation of the salt of a HMG-CoA reductase inhibitor with an amine, characterised in that the amine is added to a crude medium of the HMG-CoA reductase inhibitor and that said amine is selected from the group consisting of amines of the following formulae I and II:

a)



wherein:

- a1) R_1 , R_2 , R_3 and R_4 independently denote:
- a hydrogen atom;
 - a straight or a branched alkyl group having 1 to 8 carbon atoms;
 - a cycloalkyl group having 3 to 8 carbon atoms;
 - an arylalkyl group wherein the alkyl group is methyl or ethyl and the aryl group is phenyl, which is optionally substituted by an N-alkyl or N,N-dialkyl group wherein the alkyl group is alkyl having 1 to 4 carbon atoms;
 - an arylalkyl group which is optionally substituted by one or more substituents;
 - a hydroxyalkyl group having 2 to 4 carbon atoms; or
 - an aminoalkyl group having 2 to 4 carbon atoms, which are optionally substituted by an N-alkyl or N,N-dialkyl group wherein the alkyl group is alkyl having 1 to 4 carbon atoms;


X denotes a hydrogen atom, a hydroxyl group, a halogen or a methyl group;

m and n independently denote an integer from 0 to 5; or

- a2) NR_1R_2 or NR_3R_4 denote a heterocyclic ring having 3 to 7 methylene groups attached to a hydrogen atom, one of these groups being optionally substituted by an oxygen or a sulphur atom or an imine group; and X, m and n are the same as defined above;

10

b)



II

wherein:

- 15 b1) R'_1 , R'_2 , and R'_3 are the same or different and denote hydrogen, alkyl, alkenyl, amino- or hydroxy- or alkoxy- substituted alkyl or alkenyl, or substituted amino- substituted alkyl or alkenyl, provided that R'_1 , R'_2 and R'_3 are not hydrogen at the same time; or
- 20 b2) R'_1 and R'_2 , and optionally R'_3 , together with the nitrogen atom form an optionally substituted heterocyclic ring system including the nitrogen atom as a ring member, and optionally including an additional hetero atom, and if R'_3 is not part of the ring system it is independently
- 25 selected from hydrogen, alkyl, alkenyl, amino- or hydroxy- or alkoxy- substituted alkyl, or substituted amino-substituted alkyl; or
- b3) R'_1 is an optionally substituted cyclic group of general formula III,

30




III

wherein m is zero or an integer from 1 to 5, R' is optionally substituted aliphatic hydrocarbon cyclic system having 3 to 8 carbon atoms in the ring, R'_4 is hydrogen, alkyl, amino- or hydroxy- or alkoxy- substituted alkyl, substituted amino- substituted alkyl, or a group of the same general formula as R'_1 as defined herein above; R'_2 and R'_3 are the same as R'_1 or hydrogen, alkyl, alkenyl, amino- or hydroxy- or alkoxy- substituted alkyl, or substituted amino- substituted alkyl or alkenyl; or

b4) R'_1 is an optionally substituted aryl group of general formula IV:

15



wherein R'_5 is hydrogen or one or more substituents, and m is zero or an integer from 1 to 5; and R'_2 and R'_3 may be independently hydrogen, alkyl, amino- or hydroxy- or alkoxy- substituted alkyl, or substituted amino- substituted alkyl, or groups of the same general formula R'_1 .

6. The process according to claim 5, wherein the amine is selected from the group consisting of (\pm)-1,2-dimethylpropylamine, 3-(2-aminoethylamino)-propylamine, n-butylamine, secondary butylamine, tertiary butylamine, dibutylamine, tertiary amylamine, cyclopentylamine, cyclohexylamine, cycloheptylamine, dicyclohexylamine, N-methylcyclohexylamine, N,N'-diisopropylethylenediamine, N,N'-diethylenediamine, N-methyl-1,3-propanediamine, N-methylethylenediamine, N,N,N',N'-tetramethyl-1,2-diamino-

ethane, N,N,N',N'-tetramethyl-1,4-diaminobutane,
N,N,N',N'-tetramethyl-1,6-diaminohexane, 1,2-dipiperidin-
ethane, dipiperidinemethane, 2-amino-3,3-dimethylbutane,
N,N-dimethylcyclohexylamine, neopentylamine, adamantyl-
5 amine, N,N-diethylcyclohexylamine, N-isopropylcyclo-
hexylamine, N-methylcyclohexylamine, cyclobutylamine and
norbornylamine.

7. The process according to claim 5, wherein the amine
10 is selected from the group consisting of n-butylamine,
secondary butylamine, tertiary butylamine, dibutylamine,
tertiary amylamine, cyclohexylamine, dicyclohexylamine, N-
methylcyclohexylamine and N,N'-diisopropylethylenediamine.

15 8. The process according to any one of claims 5 to 7,
wherein the HMG-CoA reductase inhibitor is selected from
the group consisting of mevastatin, pravastatin, lova-
statin, simvastatin, fluvastatin and atorvastatin.


20 9. The process according to any one of claims 5 to 8,
wherein said crude medium is derived from a fermentation
broth containing the crude HMG-CoA reductase inhibitor.

10. The process according to claim 9, wherein said crude
medium has been obtained from the fermentation broth by a
25 process including a step of extracting the crude HMG-CoA
reductase inhibitor into an organic solvent.

11. The process according to any one of claims 5 to 8,
wherein said crude medium is derived from a reaction
30 mixture containing the crude HMG-CoA reductase inhibitor.

12. The process according to claim 11, wherein said reaction mixture has been obtained by semi or total synthesis of the HMG-CoA reductase inhibitor.
- 5 13. The process according to any one of claims 5 to 12, wherein said crude medium is present in an organic solvent which is selected from the group consisting of ethyl acetate, ether and acetonitrile.
- 10 14. The process according to any one of claims 5 to 13, wherein the HMG-CoA reductase inhibitor in said crude medium is in the acid form.
- 15 15. The process according to any one of claims 5 to 14, comprising the following steps:
- a) contacting the medium containing the HMG-CoA reductase inhibitor with the amine,
 - b) optionally: conventionally forming crystallisation nuclei,
 - 20 c) filtering the crystals crystallised out,
 - d) washing the crystals with an organic solvent, and
 - e) drying the crystals.
- 25 16. The process according to claim 15, wherein the crystallisation is carried out at temperature between 0 and 30°C.
- 30 17. The process according to claim 16, wherein the crystallisation is carried out at temperature between 4 and 22°C.

18. The use of the salt of a HMG-CoA reductase inhibitor with an amine as a processing aid, a starting substance or an intermediate substance in a process for preparing the HMG-CoA reductase inhibitor which is (i) in a purified form, (ii) in a modified form, (iii) in a pharmaceutically active salt form, or (iv) in the lactone form, characterised in that said amine is selected from the group consisting of amines of the following formulae I and II:
- 10 II:
- a)



15 wherein:

- a1) R_1 , R_2 , R_3 and R_4 independently denote:
- a hydrogen atom;
 - a straight or a branched alkyl group having 1 to 8 carbon atoms;
 - 20 • a cycloalkyl group having 3 to 8 carbon atoms;
 - an arylalkyl group wherein the alkyl group is methyl or ethyl and the aryl group is phenyl, which is optionally substituted by an N-alkyl or N,N-dialkyl group wherein the alkyl group is alkyl having 1 to 4 carbon atoms;
 - 25 • an arylalkyl group which is optionally substituted by one or more substituents;
 - a hydroxyalkyl group having 2 to 4 carbon atoms; or
 - an aminoalkyl group having 2 to 4 carbon atoms, which are optionally substituted by an N-alkyl or N,N-dialkyl group wherein the alkyl group is alkyl having 1 to 4 carbon atoms;
 - 30
- X denotes a hydrogen atom, a hydroxyl group, a halogen or a methyl group;

m and n independently denote an integer from 0 to 5; or

- a2) NR_1R_2 or NR_3R_4 denote a heterocyclic ring having 3 to 7 methylene groups attached to a hydrogen atom, one of these groups being optionally substituted by an oxygen or a sulphur atom or an imine group; and X , m and n are the same as defined above;



wherein:


- b1) R'_1 , R'_2 , and R'_3 are the same or different and denote hydrogen, alkyl, alkenyl, amino- or hydroxy- or alkoxy- substituted alkyl or alkenyl, or substituted amino- substituted alkyl or alkenyl, provided that R'_1 , R'_2 and R'_3 are not hydrogen at the same time; or
- b2) R'_1 and R'_2 , and optionally R'_3 , together with the nitrogen atom form an optionally substituted heterocyclic ring system including the nitrogen atom as a ring member, and optionally including an additional hetero atom, and if R'_3 is not part of the ring system it is independently selected from hydrogen, alkyl, alkenyl, amino- or hydroxy- or alkoxy- substituted alkyl, or substituted amino- substituted alkyl; or
- b3) R'_1 is an optionally substituted cyclic group of general formula III,



wherein m is zero or an integer from 1 to 5, R' is optionally substituted aliphatic hydrocarbon cyclic system

having 3 to 8 carbon atoms in the ring, R'₄ is hydrogen, alkyl, amino- or hydroxy- or alkoxy- substituted alkyl, substituted amino- substituted alkyl, or a group of the same general formula as R'₁ as defined herein above; R'₂ and R'₃ are the same as R'₁ or hydrogen, alkyl, alkenyl, amino- or hydroxy- or alkoxy- substituted alkyl, or substituted amino- substituted alkyl or alkenyl; or
 b4) R'₁ is an optionally substituted aryl group of general formula IV:

10



15

wherein R'₅ is hydrogen or one or more substituents, and *m* is zero or an integer from 1 to 5; and R'₂ and R'₃ may be independently hydrogen, alkyl, amino- or hydroxy- or alkoxy- substituted alkyl, or substituted amino- substituted alkyl, or groups of the same general formula R'₁.

20

19. The use according to claim 18, wherein the amine is selected from the group consisting of (±)-1,2-dimethylpropylamine, 3-(2-aminoethylamino)-propylamine, *n*-butylamine, secondary butylamine, tertiary butylamine, dibutylamine, tertiary amylamine, cyclopentylamine, cyclohexylamine, cycloheptylamine, dicyclohexylamine, *N*-methylcyclohexylamine, *N,N'*-diisopropylethylenediamine, *N,N'*-diethylenediamine, *N*-methyl-1,3-propanediamine, *N*-methylethylenediamine, *N,N,N',N'*-tetramethyl-1,2-diaminoethane, *N,N,N',N'*-tetramethyl-1,4-diaminobutane, *N,N,N',N'*-tetramethyl-1,6-diaminohexane, 1,2-dipiperidinethane, dipiperidinemethane, 2-amino-3,3-

30

dimethylbutane, N,N-dimethylcyclohexylamine,
neopentylamine, adamantylamine, N,N-diethylcyclohexylamine,
N-isopropylcyclohexylamine, N-methylcyclohexylamine,
cyclobutylamine and norborylamine.

5

20. The use according to claim 18, wherein the amine is
selected from the group consisting of n-butylamine,
secondary butylamine, tertiary butylamine, dibutylamine,
tertiary amylamine, cyclohexylamine, dicyclohexylamine, N-
10 methylcyclohexylamine and N,N'-diisopropylethylenediamine.

21. The use according to any one of claims 18 to 20,
wherein the HMG-CoA reductase inhibitor is selected from
the group consisting of mevastatin, pravastatin,
15 lovastatin, simvastatin, fluvastatin and atorvastatin.

22. The use according to claim 18, wherein said purified
form is prepared by crystallisation.

23. The use according to claim 18, wherein said modified
20 form is prepared by chemical modification.

24. The use according to claim 18, wherein said modified
form is prepared by biotechnological modification.

25 25. The use according to claim 18, wherein said
pharmaceutically active salt form is the metal salt.

26. The use according to claim 25, wherein said metal
salt is sodium salt or calcium salt.

27. A process for the isolation and/or purification of a HMG-CoA reductase inhibitor, characterised in that the amine salt of the HMG-CoA reductase inhibitor as defined
5 in any one of claims 18 to 20 is used for preparing and isolating the HMG-CoA reductase inhibitor by means of crystallisation.
28. The process according to claim 27, wherein the amine
10 salt of mevastatin, pravastatin, lovastatin, simvastatin, fluvastatin or atorvastatin is prepared and isolated.
29. The process according to claim 28, wherein the TBA
15 amine salt of mevastatin, pravastatin, lovastatin, simvastatin, fluvastatin or atorvastatin is prepared and isolated.
30. A process for the preparation of a semisynthetic HMG-CoA reductase inhibitor, characterised in that a starting
20 substance used is the amine salt of a HMG-CoA reductase inhibitor as defined in any one of claims 18 to 20.
31. The process according to claim 30, wherein the amine
25 salt of lovastatin is used as the starting substance for the preparation of simvastatin.
32. The process according to claim 31, wherein the TBA
salt of lovastatin is used as the starting substance.
33. A process for the biotechnological modification of a
30 HMG-CoA reductase inhibitor by using microorganisms or

enzymatic systems thereof, characterised in that one of the components used in the medium is the amine salt of a HMG-reductase inhibitor as defined in any one of claims 18 to 20.

5

34. The process according to claim 33, wherein the amine salt of mevastatin is used in the medium.

10 35. The process according to claim 33 or 34, wherein the amine salt of pravastatin is produced by the biotechnological process.

36. The process according to claim 35, wherein the amine salt of pravastatin is the TBA salt.

15

37. A process for the preparation of the pharmaceutically acceptable salt of a HMG-CoA reductase inhibitor, characterised in that the HMG-CoA reductase inhibitor in the form of the pharmaceutically acceptable salts is
20 prepared by using as the starting substance the amine salt of a HMG-CoA reductase inhibitor as defined in any one of claims 18 to 20.

25 38. The process according to claim 37, wherein the pharmaceutically active salt prepared is the metal salt.

39. The process according to claim 38, wherein the HMG-CoA reductase inhibitor prepared is the sodium salt of pravastatin or fluvastatin.

30

40. The process according to claim 38, wherein the HMG-CoA reductase inhibitor prepared is the calcium salt of atorvastatin.

5 41. A process for the preparation of a HMG-CoA reductase inhibitor in the lactone form, characterised in that the amine salt of a HMG-CoA reductase inhibitor as defined in claims 18 to 20 is used as the starting substance for the preparation of the HMG-CoA reductase inhibitor in the
10 lactone form.

42. The process according to claim 41, wherein the HMG-CoA reductase inhibitor prepared in the lactone form is lovastatin, mevastatin or simvastatin.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 99/01554

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07C69/013 C07C69/30 C07D309/30 C07C211/07 C07C211/14
 C07C211/09 C07C211/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 223 415 A (CONDER ET. AL.) 29 June 1993 (1993-06-29) column 7, line 25 -column 8, line 42; claims; examples 7-9	1-42
Y	US 4 319 039 A (ALBERS-SCHONBERG) 9 March 1982 (1982-03-09) cited in the application column 4, line 37 - line 59; claims; examples 13,15,16	1-42
Y	EP 0 065 835 A (SANKYO COMPANY LTD.) 1 December 1982 (1982-12-01) cited in the application page 6, line 1 -page 7, line 16; claims; examples	1-42
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

9 December 1999

Date of mailing of the international search report

16/12/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Heips, I

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 99/01554

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 456 214 A (E.R. SQUIBB & SONS) 13 November 1991 (1991-11-13) claims; examples ---	1-42
A	US 5 403 860 A (KURABAYASHI ET. AL.) 4 April 1995 (1995-04-04) cited in the application column 41, line 39 - line 64; claims; example 11E ---	1-42
A	US 5 763 646 A (KUMAR ET. AL.) 9 June 1998 (1998-06-09) cited in the application claims; examples -----	1-42

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 99/01554

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5223415 A	29-06-1993	AT 164886 T	15-04-1998
		AU 3585393 A	03-09-1993
		CA 2129661 A	19-08-1993
		CN 1083111 A	02-03-1994
		DE 69317880 D	14-05-1998
		DE 69317880 T	24-12-1998
		DK 625208 T	11-05-1998
		EP 0625208 A	23-11-1994
		ES 2114040 T	16-05-1998
		JP 7505768 T	29-06-1995
		LV 12241 B	20-08-1999
		MX 9300634 A	30-06-1994
		WO 9316188 A	19-08-1993
		CA 2053000 A,C	16-04-1992
		DE 69116107 D	15-02-1996
		DE 69116107 T	05-09-1996
		EP 0486153 A	20-05-1992
		JP 2690227 B	10-12-1997
		JP 4321680 A	11-11-1992
US 4319039 A	09-03-1982	US 4231938 A	04-11-1980
		AR 224008 A	15-10-1981
		AT 2620 T	15-03-1983
		AU 535944 B	12-04-1984
		AU 5901780 A	18-12-1980
		BA 98222 B	02-08-1999
		BG 61205 B	28-02-1997
		CA 1161380 A	31-01-1984
		CS 221919 B	29-04-1983
		DD 157344 A	03-11-1982
		DK 254180 A,B,	16-12-1980
		EG 16957 A	30-06-1990
		EP 0022478 A	21-01-1981
		ES 492384 A	01-06-1981
		FI 801857 A,B,	16-12-1980
		GR 69216 A	07-05-1982
		IE 49685 B	27-11-1985
		IL 60219 A	31-05-1985
		JP 1518752 C	07-09-1989
		JP 57163374 A	07-10-1982
		JP 63066306 B	20-12-1988
		JP 1319910 C	29-05-1986
		JP 56008689 A	29-01-1981
		JP 58016875 B	02-04-1983
		KR 8302438 A	26-10-1983
		NO 801775 A,B,	16-12-1980
		NZ 193922 A	25-05-1982
		PH 16913 A	12-04-1984
		PL 224920 A	27-03-1981
		PT 71371 A,B	01-07-1980
		RO 79487 A	06-07-1982
		SI 8011582 A	30-06-1997
		US 4294926 A	13-10-1981
		YU 152880 A	30-04-1983
		ZA 8003545 A	27-01-1982
		ZW 13480 A	03-02-1982
		HR 940098 B	30-04-1996
		US 4342767 A	03-08-1982

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 99/01554

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0065835 A	01-12-1982	JP 1039431 B	21-08-1989
		JP 1554016 C	04-04-1990
		JP 57185275 A	15-11-1982
		AT 16488 T	15-11-1985
		CA 1197850 A	10-12-1985
		US 4479965 A	30-10-1984
		US 4695587 A	22-09-1987
EP 456214 A	13-11-1991	US 5089523 A	18-02-1992
		CA 2040530 A	12-11-1991
		JP 4226941 A	17-08-1992
US 5403860 A	04-04-1995	US 5658942 A	19-08-1997
		AT 95178 T	15-10-1993
		AU 2439788 A	04-05-1989
		CA 1336598 A	08-08-1995
		DE 3884555 D	04-11-1993
		DE 3884555 T	21-04-1994
		DK 599388 A	28-04-1989
		EP 0314435 A	03-05-1989
		ES 2011427 T	16-11-1994
		FI 884968 A,B,	28-04-1989
		GR 89300123 T	31-01-1990
		HK 1005734 A	22-01-1999
		IE 63960 B	28-06-1995
		JP 2000255 A	05-01-1990
		JP 2542429 B	09-10-1996
		KR 9501633 B	27-02-1995
		US 4997848 A	05-03-1991
US 5763646 A	09-06-1998	AU 693401 A	25-06-1998
		CZ 9702649 A	12-08-1998
		EP 0864569 A	16-09-1998
		HR 970435 A	31-12-1998
		SI 9700202 A	31-08-1998
		SK 116797 A	09-09-1998

THIS PAGE BLANK (USPT